Menu
The Emphysema and COPD Research Center is participating in several clinical research studies investigating newer treatments for patients with COPD.
In addition, it maintains an active registry for patient participation in clinical research trials. The current research activities include:
We are enrolling healthy young adults 25-35 years old with no pre-existing lung disease to test their lung function and imaging to determine factors in young adulthood which might affect lung health later in life.
Targeted lung denervation involves a bronchoscopic procedure and heat ablation of vagus nerve fibers that cause lung airway muscle spasms and mucus production. It is being tested to reduce COPD flare-ups and hospitalizations.
Tozorakimab is an injected antibody against IL-33 a protein that promotes inflammation and COPD flare-ups. The trials are to prove whether monthly injections reduce flare-ups and symptoms in patients with COPD.
This study compares azithromycin and roflumilast to prevent COPD flare-ups and hospitalizations. This trial works with your doctor to select either azithromycin or roflumilast which are both approved drugs to reduce flare-ups, although it is unclear which treatment is better. No research visits required, only medical record review.
Benralizumab is an injected antibody against IL-5 receptors, approved for asthma and now being tested to reduce COPD flare-ups in patients with high blood eosinophils. The trial involves monthly injections.
myAirvo 3 is a device which delivers either air or oxygen via a special humidified nasal cannula at high flow rates. It is being tested in recently hospitalized patients to reduce the risk of COPD flare-ups and hospitalizations.
